DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 065085
NDA 065085 describes MUPIROCIN, which is a drug marketed by Glenmark Pharms Inc, Fougera Pharms, Glenmark Pharms, Perrigo New York, Taro, and Teva, and is included in six NDAs. It is available from twenty-nine suppliers. Additional details are available on the MUPIROCIN profile page.
The generic ingredient in MUPIROCIN is mupirocin. There are thirteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
The generic ingredient in MUPIROCIN is mupirocin. There are thirteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
Summary for 065085
| Tradename: | MUPIROCIN |
| Applicant: | Teva |
| Ingredient: | mupirocin |
| Patents: | 0 |
| Therapeutic Class: | Antibacterials |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 065085
| Mechanism of Action | RNA Synthetase Inhibitors |
Medical Subject Heading (MeSH) Categories for 065085
Suppliers and Packaging for NDA: 065085
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 065085 | ANDA | Teva Pharmaceuticals USA, Inc. | 0093-1010 | N | 0093-1010-42 |
| MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 065085 | ANDA | Rebel Distributors Corp | 42254-137 | E | 42254-137-22 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | OINTMENT;TOPICAL | Strength | 2% | ||||
| Approval Date: | Nov 7, 2003 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
